NAM
SRPT icon

NorthCrest Asset Manangement’s Sarepta Therapeutics SRPT Stock Holding History

NorthCrest Asset Manangement’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,112
Closed -$258K – 971
2026
Q1 		$258K Sell
11,112
-7,917
-42% -$153K 0.01% 666
2025
Q4 		$401K Buy
+19,029
New +$401K 0.01% 606

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

NorthCrest Asset Manangement's SRPT Position: Q2 2026 in Review

NorthCrest Asset Manangement sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 11,112 shares — an estimated $258K sold.

NorthCrest Asset Manangement first reported a position in SRPT in Q4 2025 and held it in 2 quarters. The position peaked at $401K in Q4 2025. 123 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • NorthCrest Asset Manangement reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
  • NorthCrest Asset Manangement sold 11,112 Sarepta Therapeutics shares in Q2 2026, an estimated $258K.
  • NorthCrest Asset Manangement first reported a position in Sarepta Therapeutics in Q4 2025 and held it in 2 quarters.
  • NorthCrest Asset Manangement's Sarepta Therapeutics position peaked at $401K in Q4 2025.
  • 123 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on NorthCrest Asset Manangement's 13F filing for Q2 2026, filed 15 Jul 2026.